Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy

Autor: Theresa Yuraszeck, Michael A. Tortorici, Billie L. Durn, Hans-Peter Hartung, Orell Mielke, Vera Bril, Ivo N. van Schaik, David R. Cornblath, Marc Pfister, Gen Sobue, Ingemar S. J. Merkies, Xuewen Ma, Michaela Praus, John-Philip Lawo, Richard A. Lewis, Petra M. Jauslin

Publikováno v: CPT: Pharmacometrics and Systems Pharmacology, 10(8), 839-850. Wiley
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 839-850 (2021)

The two main objectives of this analysis were to (i) characterize the relationship between immunoglobulin (Ig) exposure and chronic inflammatory demyelinating polyneuropathy (CIDP) disease severity using data from 171 patients with CIDP who received

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09b76a98d0b112baca25fdca06cf2202
https://doi.org/10.1002/psp4.12647

Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis

Autor: Petra M. Jauslin, Azher Hussain, Suresh Vatakuti, Hanbin Li, Thomas Kerbusch, Larissa Wenning, Pooja Kulkarni

Publikováno v: Clinical pharmacokinetics. 58(8)

Tildrakizumab is an anti-interleukin-23p19 monoclonal antibody recently approved for the treatment of chronic plaque psoriasis. This analysis characterizes the population pharmacokinetics of subcutaneous tildrakizumab and identifies covariates influe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0dc9edfb4b8452e4a97b6788fe2b53f
https://pubmed.ncbi.nlm.nih.gov/30915660

Modeling of 24-Hour Glucose and Insulin Profiles of Patients With Type 2 Diabetes

Autor: Mats O. Karlsson, Nicolas Frey, Petra M. Jauslin

Publikováno v: The Journal of Clinical Pharmacology. 51:153-164

A model able to simultaneously characterize and simulate 24-hour glucose and insulin profiles following multiple meal tests was developed, extending an integrated glucose-insulin model for oral glucose tolerance tests that was previously published. T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0505cffa736f0a1fa35db34c381a5f
https://doi.org/10.1177/0091270010362536

An Integrated Glucose-Insulin Model to Describe Oral Glucose Tolerance Test Data in Type 2 Diabetics

Autor: Hanna E. Silber, Ronald Gieschke, Mats O. Karlsson, Petra M. Jauslin, Karin Jorga, Ulrika S. H. Simonsson, Nicolas Frey

Publikováno v: The Journal of Clinical Pharmacology. 47:1244-1255

An integrated model for the glucose-insulin system describing oral glucose tolerance test data was developed, extending on a previously introduced model for intravenous glucose provocations. Model extensions comprised the description of glucose absor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::682f481a1460b72cd607b4d1ffc16d04
https://doi.org/10.1177/0091270007302168

An integrated model for the glucose-insulin system

Autor: Petra M. Jauslin, Hanna E. Silber, Mats O. Karlsson, Nicolas Frey

Publikováno v: Basicclinical pharmacologytoxicology. 106(3)

The integrated glucose-insulin model was originally developed on a variety of intravenous glucose provocation experiments in healthy volunteers and type 2 diabetic patients. The model, which simultaneously describes time-courses of glucose and insuli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15346caaf3654320cf5bab9849ca829c
https://pubmed.ncbi.nlm.nih.gov/20050839